Humoral rejection is refractory to conventional high-dose corticosteroid pulse therapy and invariably requires the addition of depleting antibodies, either polyclonal antilymphocyte agents or OKT3.

There has been a great deal of recent work that has used the combination of plasmapheresis and intravenous immunoglobulin (IVIG) to treat humoral rejection. It seems to be an important advance.

Since its first description by Ehrlich in the late 1890s and subsequent characterization by Bordet, the complement cascade has been thought to have important and varied roles in the immune response.

A research study at the University of Chicago has found that in pregnancy, while the T cell response to a fetus becomes tolerant to allow for successful pregnancy, the part of the immune system that ...

To investigate the role of DSAs in allo-SCT, we first examined a case of cord blood allograft rejection. DSA and donor HLA-specific cytotoxic T lymphocyte (CTL) recognizing the same alloantigen of the ...

IN recent months it has become increasingly evident that humoral antibodies as well as cellular immune mechanisms sometimes play an active part in the rejection of human kidney transplants. Several ...

Transplant rejection is a major concern associated with kidney transplantation (KT). Researchers have linked terminally differentiated effector memory (TEMRA) CD8 + T cell presence and activity with ...

We previously reported results of our study of combined kidney and bone marrow transplantation without maintenance immunosuppression. We extended the study to include five additional patients. Here we ...

Amid the debate over which combination of immunosuppressive agents works best in helping patients fight off rejection of their new heart after transplant surgery, a new study led by researchers at the ...